P. Kelly Marcom

5.3k total citations
49 papers, 1.8k citations indexed

About

P. Kelly Marcom is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, P. Kelly Marcom has authored 49 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 30 papers in Oncology, 30 papers in Cancer Research and 13 papers in Pulmonary and Respiratory Medicine. Recurrent topics in P. Kelly Marcom's work include Breast Cancer Treatment Studies (22 papers), Cancer Treatment and Pharmacology (13 papers) and Advanced Breast Cancer Therapies (10 papers). P. Kelly Marcom is often cited by papers focused on Breast Cancer Treatment Studies (22 papers), Cancer Treatment and Pharmacology (13 papers) and Advanced Breast Cancer Therapies (10 papers). P. Kelly Marcom collaborates with scholars based in United States, Germany and Canada. P. Kelly Marcom's co-authors include Eric P. Winer, Harold J. Burstein, Clifford A. Hudis, Jeffrey R. Marks, Andrew D. Seidman, Donald A. Berry, Peter C. Ungaro, Diana Lake, Hyman B. Muss and Charles L. Shapiro and has published in prestigious journals such as JAMA, Journal of Clinical Oncology and Cancer Research.

In The Last Decade

P. Kelly Marcom

47 papers receiving 1.8k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
P. Kelly Marcom United States	20	1.1k	669	378	334	324	49	1.8k
Edda Simoncini Italy	26	1.7k 1.5×	1.1k 1.6×	440 1.2×	360 1.1×	212 0.7×	99	2.5k
Jonathan D. Marotti United States	21	1.3k 1.2×	1.1k 1.7×	621 1.6×	570 1.7×	213 0.7×	84	2.5k
Foluso O. Ademuyiwa United States	28	1.3k 1.1×	818 1.2×	468 1.2×	503 1.5×	242 0.7×	91	2.2k
Victoria Sopik Canada	21	719 0.6×	825 1.2×	371 1.0×	400 1.2×	133 0.4×	37	1.6k
B. Norris Canada	15	1.6k 1.4×	1.1k 1.7×	443 1.2×	302 0.9×	145 0.4×	25	2.2k
Holm Eggemann Germany	22	694 0.6×	651 1.0×	231 0.6×	382 1.1×	145 0.4×	76	1.6k
Eva Carrasco Spain	22	1.5k 1.3×	1.1k 1.7×	358 0.9×	302 0.9×	112 0.3×	77	2.0k
Debora Fumagalli Belgium	24	2.2k 1.9×	1.2k 1.8×	1.0k 2.7×	211 0.6×	279 0.9×	83	3.3k
Jo Anne Zujewski United States	16	710 0.6×	739 1.1×	317 0.8×	440 1.3×	179 0.6×	29	1.6k
J. Thaddeus Beck United States	19	1.4k 1.2×	619 0.9×	551 1.5×	401 1.2×	185 0.6×	74	2.1k

Countries citing papers authored by P. Kelly Marcom

Since Specialization

Citations

This map shows the geographic impact of P. Kelly Marcom's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by P. Kelly Marcom with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites P. Kelly Marcom more than expected).

Fields of papers citing papers by P. Kelly Marcom

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by P. Kelly Marcom. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by P. Kelly Marcom. The network helps show where P. Kelly Marcom may publish in the future.

Co-authorship network of co-authors of P. Kelly Marcom

This figure shows the co-authorship network connecting the top 25 collaborators of P. Kelly Marcom. A scholar is included among the top collaborators of P. Kelly Marcom based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with P. Kelly Marcom. P. Kelly Marcom is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Force, Jeremy, Jennifer K. Plichta, Gretchen Kimmick, et al.. (2019). Abstract P3-08-07: Distinct biological signatures describe differences in BRCA mutated subgroups. Cancer Research. 79(4_Supplement). P3–8. 1 indexed citations

Saha, Ashirbani, et al.. (2018). Multivariate machine learning models for prediction of pathologic response to neoadjuvant therapy in breast cancer using MRI features: a study using an independent validation set. Breast Cancer Research and Treatment. 173(2). 455–463. 134 indexed citations

Force, Jeremy, Lynn Howie, Sara Abbott, et al.. (2018). Early Stage HER2-Positive Breast Cancers Not Achieving a pCR From Neoadjuvant Trastuzumab- or Pertuzumab-Based Regimens Have an Immunosuppressive Phenotype. Clinical Breast Cancer. 18(5). 410–417. 22 indexed citations

Buchanan, Adam H., Corrine I. Voils, Joellen M. Schildkraut, et al.. (2016). Adherence to Recommended Risk Management among Unaffected Women with a BRCA Mutation. Journal of Genetic Counseling. 26(1). 79–92. 28 indexed citations

Ruddy, Kathryn J., Hao Guo, William T. Barry, et al.. (2015). Chemotherapy-related amenorrhea after adjuvant paclitaxel–trastuzumab (APT trial). Breast Cancer Research and Treatment. 151(3). 589–596. 49 indexed citations

Magbanua, Mark Jesus M., Lisa A. Carey, Amy DeLuca, et al.. (2014). Circulating Tumor Cell Analysis in Metastatic Triple-Negative Breast Cancers. Clinical Cancer Research. 21(5). 1098–1105. 32 indexed citations

Hamilton, Erika, Jeffrey Peppercorn, P. Kelly Marcom, et al.. (2013). Clinical impact of febrile neutropenia (FN) increase among patients receiving adjuvant docetaxel/cyclophosphamide (TC) chemotherapy compared to TC plus pegfilgrastim for breast cancer.. Journal of Clinical Oncology. 31(15_suppl). 1076–1076. 4 indexed citations

Hamilton, E.P., P. Kelly Marcom, Novera Herbert Spector, et al.. (2013). Abstract S4-03: Exome sequencing reveals clinically actionable mutations in the pathogenesis and metastasis of triple negative breast cancer. Cancer Research. 73(24_Supplement). S4–3. 3 indexed citations

Greenup, Rachel A., Adam H. Buchanan, Wendy Lorizio, et al.. (2013). Prevalence of BRCA Mutations Among Women with Triple-Negative Breast Cancer (TNBC) in a Genetic Counseling Cohort. Annals of Surgical Oncology. 20(10). 3254–3258. 170 indexed citations

10.

Tolaney, SM, DA Yardley, Beverly Moy, et al.. (2013). Abstract S1-04: A phase II study of adjuvant paclitaxel (T) and trastuzumab (H) (APT trial) for node-negative, HER2-positive breast cancer (BC). Cancer Research. 73(24_Supplement). S1–4. 22 indexed citations

11.

Marcom, P. Kelly, et al.. (2012). Abstract P4-09-01: Retrospective evaluation of precision of gene-expression-based signatures of prognosis and tumor biology in replicate surgical biospecimens from patients with breast cancer. Cancer Research. 72(24_Supplement). P4–9. 1 indexed citations

12.

Herold, Christina I., Vijaya Chadaram, Bercedis L. Peterson, et al.. (2011). Phase II Trial of Dasatinib in Patients with Metastatic Breast Cancer Using Real-Time Pharmacodynamic Tissue Biomarkers of Src Inhibition to Escalate Dosing. Clinical Cancer Research. 17(18). 6061–6070. 64 indexed citations

13.

Marcom, P. Kelly, Joseph Geradts, John A. Olson, et al.. (2010). A randomized phase II trial evaluating the performance of genomic expression profiles to direct the use of preoperative chemotherapy for early-stage breast cancer.. Journal of Clinical Oncology. 28(15_suppl). TPS102–TPS102. 2 indexed citations

14.

Ellis, Matthew J., Feng Gao, Farrokh Dehdashti, et al.. (2009). Lower-Dose vs High-Dose Oral Estradiol Therapy of Hormone Receptor–Positive, Aromatase Inhibitor–Resistant Advanced Breast Cancer. JAMA. 302(7). 774–774. 204 indexed citations

15.

Seidman, Andrew D., Donald A. Berry, Constance Cirrincione, et al.. (2008). Randomized Phase III Trial of Weekly Compared With Every-3-Weeks Paclitaxel for Metastatic Breast Cancer, With Trastuzumab for all HER-2 Overexpressors and Random Assignment to Trastuzumab or Not in HER-2 Nonoverexpressors: Final Results of Cancer and Leukemia Group B Protocol 9840. Journal of Clinical Oncology. 26(10). 1642–1649. 446 indexed citations

16.

Liu, Minetta C., George D. Demetri, Donald A. Berry, et al.. (2008). Dose-escalation of filgrastim does not improve efficacy: Clinical tolerability and long-term follow-up on CALGB study 9141 adjuvant chemotherapy for node-positive breast cancer patients using dose-intensified doxorubicin plus cyclophosphamide followed by paclitaxel. Cancer Treatment Reviews. 34(3). 223–230. 11 indexed citations

17.

Carey, LA, Hope S. Rugo, P. Kelly Marcom, et al.. (2008). TBCRC 001: EGFR inhibition with cetuximab added to carboplatin in metastatic triple-negative (basal-like) breast cancer. Journal of Clinical Oncology. 26(15_suppl). 1009–1009. 133 indexed citations

18.

Anders, Carey K., P. Kelly Marcom, Bercedis L. Peterson, et al.. (2008). A Pilot Study of Predictive Markers of Chemotherapy-Related Amenorrhea Among Premenopausal Women with Early Stage Breast Cancer. Cancer Investigation. 26(3). 286–295. 96 indexed citations

19.

Dressman, Holly K., Christopher Hans, Andrea H. Bild, et al.. (2006). Gene Expression Profiles of Multiple Breast Cancer Phenotypes and Response to Neoadjuvant Chemotherapy. Clinical Cancer Research. 12(3). 819–826. 121 indexed citations

20.

Burstein, Harold J., William P. Petros, Kathryn Clarke, et al.. (1999). Phase I study of Doxil and vinorelbine in metastatic breast cancer. Annals of Oncology. 10(9). 1113–1116. 41 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact